RAS is one of the most frequently altered oncogenes, yet RAS-driven tumors are largely
refractory to anticancer therapies. Fedele and colleagues demonstrate that SHP2 inhibitors …

Adaptive resistance to MEK inhibitors (MEKi) typically occurs via induction of genes for
different receptor tyrosine kinases (RTK) and/or their ligands, even in tumors of the same …

FGFR1 was recently shown to be activated as part of a compensatory response to prolonged
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …

Despite the promising antitumor activity of RAF/MEK inhibitors for RAS-driven cancers, not
all patients respond to these therapies. Adaptive resistance has been reported as a major …

The non-receptor protein tyrosine phosphatase SHP2 (encoded by PTPN11) is a critical
component of RAS/MAPK signaling by acting upstream of RAS to promote oncogenic …

The non-receptor protein tyrosine phosphatase SHP2 (PTPN11) plays an important role in
the regulation of RAS/MAPK signal transduction downstream of growth factor receptor …

Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …

The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by
PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine …

Src homology 2 domain-containing phosphatase (SHP2) is a non-receptor protein
phosphatase that transduces signals from upstream receptor tyrosine kinases (RTKs)/non …

RMC-4630 is a potent, selective, orally bioavailable allosteric inhibitor of SHP2, a central
node regulating RAS signaling. Consistent with preclinical observations, initial data from a …